5.43 0.08 (1.5%) | 04-23 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 6.71 ![]() |
1-year : | 7.84 ![]() |
Resists | First : | 5.75 ![]() |
Second : | 6.71 ![]() |
Pivot price | 4.2 ![]() |
|||
Supports | First : | 4.26 ![]() |
Second : | 3.33 |
MAs | MA(5) : | 4.74 ![]() |
MA(20) : | 4.11 ![]() |
MA(100) : | 2.72 ![]() |
MA(250) : | 1.71 ![]() |
|
MACD | MACD : | 0.2 ![]() |
Signal : | 0.1 ![]() |
%K %D | K(14,3) : | 74.1 ![]() |
D(3) : | 60.7 ![]() |
RSI | RSI(14): 66.7 ![]() |
|||
52-week | High : | 7.86 | Low : | 0.34 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BCTX ] has closed Bollinger Bands are 2.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 5.76 - 5.78 | 5.78 - 5.8 |
Low: | 4.98 - 5 | 5 - 5.02 |
Close: | 5.39 - 5.42 | 5.42 - 5.47 |
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
Wed, 23 Apr 2025
BriaCell Announces Four Clinical Data Presentations at ASCO 2025 - TradingView
Wed, 23 Apr 2025
Major Phase III Breast Cancer Treatment Update: BriaCell Unveils 4 Clinical Studies at ASCO 2025 - Stock Titan
Tue, 22 Apr 2025
BriaCell (BCTX) Advances Phase 3 Trial for Bria-IMT in Metastatic Breast Cancer | BCTX Stock News - GuruFocus
Tue, 22 Apr 2025
Fast-Tracked Phase 3 Breast Cancer Treatment Shows Major Enrollment Surge: 75 Patients Join Critical Trial - Stock Titan
Wed, 16 Apr 2025
BCTX - Briacell Therapeutics Corp Latest Stock News & Market Updates - Stock Titan
Wed, 16 Apr 2025
BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer - GlobeNewswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 4 (M) |
Shares Float | 3 (M) |
Held by Insiders | 12.9 (%) |
Held by Institutions | 14 (%) |
Shares Short | 188 (K) |
Shares Short P.Month | 202 (K) |
EPS | -4.75 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 1.22 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -158.2 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -7.33 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -22 (M) |
Levered Free Cash Flow | -11 (M) |
PE Ratio | -1.15 |
PEG Ratio | 0 |
Price to Book value | 4.45 |
Price to Sales | 0 |
Price to Cash Flow | -0.92 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |